vs
Side-by-side financial comparison of GENMAB A/S (GMAB) and ILLUMINA, INC. (ILMN), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
ILLUMINA, INC. is the larger business by last-quarter revenue ($1.1B vs $925.0M, roughly 1.2× GENMAB A/S). GENMAB A/S runs the higher net margin — 36.3% vs 16.8%, a 19.5% gap on every dollar of revenue. On growth, GENMAB A/S posted the faster year-over-year revenue change (18.7% vs -1.6%).
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab (Suzhou) Co., Ltd. in Suzhou, China. Genmab is listed on the Co...
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets, and serves more than 155 countries.
GMAB vs ILMN — Head-to-Head
Income Statement — Q2 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $925.0M | $1.1B |
| Net Profit | $336.0M | $186.0M |
| Gross Margin | 93.8% | 65.9% |
| Operating Margin | 38.9% | 15.8% |
| Net Margin | 36.3% | 16.8% |
| Revenue YoY | 18.7% | -1.6% |
| Net Profit YoY | 65.5% | 205.7% |
| EPS (diluted) | $5.42 | $1.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align — see 8-quarter trend below.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q2 25 | $925.0M | — | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | $779.0M | $1.1B | ||
| Q1 24 | — | $1.1B | ||
| Q4 23 | — | $1.1B | ||
| Q3 23 | — | $1.2B | ||
| Q2 23 | — | $1.1B |
| Q2 25 | $336.0M | — | ||
| Q4 24 | — | $186.0M | ||
| Q3 24 | — | $705.0M | ||
| Q2 24 | $203.0M | $-2.0B | ||
| Q1 24 | — | $-126.0M | ||
| Q4 23 | — | $-754.0M | ||
| Q3 23 | — | $-234.0M | ||
| Q2 23 | — | $3.0M |
| Q2 25 | 93.8% | — | ||
| Q4 24 | — | 65.9% | ||
| Q3 24 | — | 69.0% | ||
| Q2 24 | 96.4% | 64.8% | ||
| Q1 24 | — | 62.0% | ||
| Q4 23 | — | 61.1% | ||
| Q3 23 | — | 62.2% | ||
| Q2 23 | — | 60.3% |
| Q2 25 | 38.9% | — | ||
| Q4 24 | — | 15.8% | ||
| Q3 24 | — | 68.6% | ||
| Q2 24 | 30.3% | -147.2% | ||
| Q1 24 | — | -10.3% | ||
| Q4 23 | — | -67.4% | ||
| Q3 23 | — | -7.5% | ||
| Q2 23 | — | -5.9% |
| Q2 25 | 36.3% | — | ||
| Q4 24 | — | 16.8% | ||
| Q3 24 | — | 65.3% | ||
| Q2 24 | 26.1% | -178.8% | ||
| Q1 24 | — | -11.7% | ||
| Q4 23 | — | -67.4% | ||
| Q3 23 | — | -19.9% | ||
| Q2 23 | — | 0.3% |
| Q2 25 | $5.42 | — | ||
| Q4 24 | — | $1.16 | ||
| Q3 24 | — | $4.42 | ||
| Q2 24 | $3.13 | $-12.48 | ||
| Q1 24 | — | $-0.79 | ||
| Q4 23 | — | $-4.77 | ||
| Q3 23 | — | $-1.48 | ||
| Q2 23 | — | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest filing — the kind of financial-strength check premium terminals charge for.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.3B | $2.4B |
| Total Assets | $6.5B | $6.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q2 25 | $1.3B | — | ||
| Q4 24 | — | $93.0M | ||
| Q3 24 | — | $70.0M | ||
| Q2 24 | $622.0M | $74.0M | ||
| Q1 24 | — | — | ||
| Q4 23 | — | $6.0M | ||
| Q3 23 | — | $6.0M | ||
| Q2 23 | — | $24.0M |
| Q2 25 | $5.3B | — | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | $4.4B | $1.4B | ||
| Q1 24 | — | $5.7B | ||
| Q4 23 | — | $5.9B | ||
| Q3 23 | — | $6.6B | ||
| Q2 23 | — | $6.7B |
| Q2 25 | $6.5B | — | ||
| Q4 24 | — | $6.3B | ||
| Q3 24 | — | $6.0B | ||
| Q2 24 | — | $6.1B | ||
| Q1 24 | — | $10.0B | ||
| Q4 23 | — | $10.1B | ||
| Q3 23 | — | $11.8B | ||
| Q2 23 | — | $11.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Net income can be massaged; cash flow is harder to fake.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $364.0M |
| Free Cash FlowOCF − Capex | — | $335.0M |
| FCF MarginFCF / Revenue | — | 30.3% |
| Capex IntensityCapex / Revenue; lower = less reinvestment burden | — | 2.6% |
| Cash ConversionOCF / Net Profit; >1× = earnings back up with cash | — | 1.96× |
| TTM Free Cash FlowTrailing 4 quarters | — | $709.0M |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q2 25 | — | — | ||
| Q4 24 | — | $364.0M | ||
| Q3 24 | — | $316.0M | ||
| Q2 24 | — | $80.0M | ||
| Q1 24 | — | $77.0M | ||
| Q4 23 | — | $139.0M | ||
| Q3 23 | — | $105.0M | ||
| Q2 23 | — | $10.0M |
| Q2 25 | — | — | ||
| Q4 24 | — | $335.0M | ||
| Q3 24 | — | $284.0M | ||
| Q2 24 | — | $49.0M | ||
| Q1 24 | — | $41.0M | ||
| Q4 23 | — | $94.0M | ||
| Q3 23 | — | $58.0M | ||
| Q2 23 | — | $-42.0M |
| Q2 25 | — | — | ||
| Q4 24 | — | 30.3% | ||
| Q3 24 | — | 26.3% | ||
| Q2 24 | — | 4.4% | ||
| Q1 24 | — | 3.8% | ||
| Q4 23 | — | 8.4% | ||
| Q3 23 | — | 4.9% | ||
| Q2 23 | — | -3.9% |
| Q2 25 | — | — | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | — | 3.0% | ||
| Q2 24 | — | 2.8% | ||
| Q1 24 | — | 3.3% | ||
| Q4 23 | — | 4.0% | ||
| Q3 23 | — | 4.0% | ||
| Q2 23 | — | 4.8% |
| Q2 25 | — | — | ||
| Q4 24 | — | 1.96× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 3.33× |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
Revenue Breakdown by Segment
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
ILMN
| Sequencing | $1.0B | 91% |
| Microarray | $101.0M | 9% |
| Investee | $7.0M | 1% |
